Medpace Holdings, Inc. $MEDP Shares Purchased by Local Pensions Partnership Investment Ltd

Local Pensions Partnership Investment Ltd increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 42,000 shares of the company’s stock after purchasing an additional 4,000 shares during the quarter. Medpace accounts for about 0.5% of Local Pensions Partnership Investment Ltd’s holdings, making the stock its 25th largest holding. Local Pensions Partnership Investment Ltd’s holdings in Medpace were worth $22,265,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Elyxium Wealth LLC purchased a new stake in Medpace in the 4th quarter worth $30,000. Allied Private Wealth LLC acquired a new position in Medpace during the second quarter worth $31,000. Basecamp Wealth Advisors LLC lifted its holdings in Medpace by 187.5% during the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Medpace in the third quarter valued at about $35,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP stock opened at $578.50 on Friday. The company has a market capitalization of $16.15 billion, a PE ratio of 33.91, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15. The firm’s 50-day moving average is $536.23 and its two-hundred day moving average is $492.35. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter last year, the firm earned $3.10 EPS. The business’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Ratings Changes

MEDP has been the subject of several research analyst reports. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. BMO Capital Markets lifted their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Truist Financial boosted their price target on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a report on Thursday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and a consensus price target of $584.18.

Insiders Place Their Bets

In other Medpace news, Director Cornelius P. Mccarthy III sold 1,140 shares of Medpace stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the sale, the director directly owned 12,275 shares in the company, valued at $7,430,916.75. This trade represents a 8.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the transaction, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 67,195 shares of company stock valued at $37,989,998 over the last 90 days. Company insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.